USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: NEUGENESIS CORPORATION
City: SAN CARLOS
State: CA
Zip+4: 94070
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (650) 508-9671

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $950,000.00 18
SBIR Phase II $1,827,000.00 4

Award List:

NEW APPROACHES TO PRODUCTION OF HLA TYPING REAGENTS

Award Year / Program / Phase: 1984 / SBIR / Phase I
Agency: HHS
Principal Investigator: Chih Ping Liu , Senior Scientist
Award Amount: $50,000.00

RAPID APPROACHES FOR PRODUCTION OF GENOMIC DNA PROBES

Award Year / Program / Phase: 1984 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kirk E. Fry , Senior Scientist
Award Amount: $50,000.00

PRODUCTION OF COMPOSITE MONOCLONAL IMMUNOGLOBULINS

Award Year / Program / Phase: 1984 / SBIR / Phase I
Agency: HHS
Principal Investigator: Chih Ping Liu , Senior Scientist
Award Amount: $50,000.00

PRODUCTION OF COMPOSITE MONOCLONAL IMMUNOGLOBULINS

Award Year / Program / Phase: 1985 / SBIR / Phase II
Agency: HHS
Principal Investigator: Chih Ping Liu , Senior Scientist
Award Amount: $500,000.00
Abstract:
Murine monoclonal antibodies are not useful for repeated administration to man because of the number of foreign antigen determinants they contain. production of human monoclonal antibodies would be desir-able for a variety of approaches in prophylaxis and therapy of disease, and also in protection… More

INTERLEUKIN 2 (IL-2) IS A RELATIVELY WELL-STUDIED LYMPHOKINE THAT PROMOTES PROLIFERATION AND DIFFERENTIATION OF T LYMPHOCYTES AND NATURAL KILLER CELLS.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kirk fry , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Interleukin 2 (il-2) is a relatively well-studied lymphokine that promotes proliferation and differentiation of t lymphocytes and natural killer cells. il-2 has potent antitumor effects when administered to experimental mice with metastatic disease. unfortunately, initial efforts to treat humans… More

WE WILL IDENTIFY AND CHARACTERIZE ALL THE MHC CLASS II BETA CHAIN GENES AND PSEUDOGENES IN A CELL LINE CONTAINING A SINGLE COPY OF THE MHC.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kirk e. fry , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
We will identify and characterize all the mhc class ii beta chain genes and pseudogenes in a cell line containing a single copy of the mhc. the sequence information obtained will be used to construct a series of vectors that permit rapid construction of hybrid human-murine class ii genes containing… More

THE OBJECTIVE IS TO DEVELOP AN IN VITRO IMMUNIZATION SYSTEM TO PRODUCE HUMAN MONOCLONAL ANTIBODIES TO CELL SURFACE ANTIGENS OF HUMAN BREAST CARCINOMA, COLON CARCINOMA, AND MALIGNANT MELANOMA.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jungsuh kim , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The objective is to develop an in vitro immunization system to produce human monoclonal antibodies to cell surface antigens of human breast carcinoma, colon carcinoma, and malignant melanoma. human monoclonal antibodies are desirable for a variety of reasons, including: a.the majority of antibodies… More

HUMAN T-CELL LYMPHOTROPHIC VIRUSES ARE COMPOSED OF AT LEAST THREE MEMBERS, INCLUDING THE HTLV-I VIRUS WHICH IS THE ETIOLOGIC AGENT OF ADULT T-CELL LEUKEMIA/LYMPHOMA AND THE RECENTLY WELL-CHARACTERIZED HTLV-III (ARV, LAV) GENOME WHICH TRANSMITS ACQUIRED

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gregory r. reyes , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Human t-cell lymphotrophic viruses are composed of at least three members, including the htlv-i virus which is the etiologic agent of adult t-cell leukemia/lymphoma and the recently well-characterized htlv-iii (arv, lav) genome which transmits acquired immune deficiency syndrome (aids). the… More

NON-A, NON-B (NANB) HEPATITIS IS A MAJOR CAUSE OF LIVER DISEASE IN BOTH THE DEVELOPED AND UNDEVELOPED COUNTRIES OF THE WORLD.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gregory r. reyes , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Non-a, non-b (nanb) hepatitis is a major cause of liver disease in both the developed and undeveloped countries of the world. while a large body of data strongly suggests an infectious agent, efforts to isolate such an agent have thus far not been rewarding. this proposal outlines steps which take… More

THE ESSENTIAL PLAN OF THIS PROPOSAL IS TO USE OOCYTE MICROINJECTION TO CREATE STRAINS OF MICE THAT ARE TOLERANT TO THE SPECIES-SPECIFIC DETERMINANTS THAT DISTINGUISH HUMAN CLASS I, DR, DC, OR SB ANTIGENS AS A GROUP FROM THEIR MURINE ANALOGUES INDEPENDENT

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kirk e. fry , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The essential plan of this proposal is to use oocyte microinjection to create strains of mice that are tolerant to the species-specific determinants that distinguish human class i, dr, dc, or sb antigens as a group from their murine analogues independent of their allelic variations. these strains of… More

HUMAN MONOCLONAL ANTIBODIES TO HLA-DR DETERMINANTS

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Paul Wu , Principal Investigator
Award Amount: $50,000.00

NEW APPROACHES TO PRODUCTION OF HLA TYPING REAGENTS

Award Year / Program / Phase: 1986 / SBIR / Phase II
Agency: HHS
Principal Investigator: Chih Ping Liu , Senior Scientist
Award Amount: $495,000.00
Abstract:
Human class ii histocompatibility antigen typing is already of substantial importance in determing disease susceptibility in individuals. present serologic methods of class ii antigen typing are limited by the polyclonal nature of many antisera, by the fact that many of the available human antisera… More

HUMAN MONOCLONAL ANTIBODIES TO HLA-DR DETERMINANTS

Award Year / Program / Phase: 1986 / SBIR / Phase II
Agency: HHS
Principal Investigator: Paul Wu , Principal Investigator
Award Amount: $500,000.00
Abstract:
The immune response in man is regulated by ordered interactions between functionally and phenotypically distinct lymphoid cells (t cells and their subsets, b cells and monocytes) in the context of ia-like molecules encoded by the hla complex of genes. thus, the products of these genes (e.g., dr, ds,… More

UNTIL VERY RECENTLY, THE SIZES OF DNA FRAGMENTS THAT COULD BE DEALT WITH BY CLONING AND ELECTROPHORETIC TECHNIQUES WEREGENERALLY ONE TO TWO ORDERS OF MAGNITUDE BELOW THOSE NEEDED FOR A PRACTICAL AND SYSTEMATIC MOLECULAR DESCRIPTION OF HUMAN DNA

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kirk fry , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Until very recently, the sizes of dna fragments that could be dealt with by cloning and electrophoretic techniques weregenerally one to two orders of magnitude below those needed for a practical and systematic molecular description of human dna relationships over the range dealt with by classical… More

MONOCLONAL ANTIBODIES TO HTLV-III/LAV

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kou hwang , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Mouse and rat monoclonal antibodies will be produced againsthtlv-iii, the human retrovirus associated with aids and a spectrum of related syndromes. gene labs will employ intacthtlv-iii virions coupled to klh as an immunogen and use a sensitive elisa assay, based on purified htlv-iii as the antigen… More

IN THIS PROJECT, GENE LABS, INC.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kou hwang , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
In this project, gene labs, inc. will produce and characterize human monoclonal antibodies to htlv-iii, the human retrovirus associated with aids and a spectrum of related syndromes. gene labs has successfully used the sbc-h20 heteromyeloma cell line as the fusion partner for the generation of… More

THE GOAL OF THIS PROPOSED RESEARCH IS TO DEFINE THE MOLECU- LAR STRUCTURES THAT DETERMINE THE ANTIGENETIC REACTIVITY OF THE HUMAN RH SYSTEM.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kou m hwang , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
The goal of this proposed research is to define the molecu- lar structures that determine the antigenetic reactivity of the human rh system. using preexisting human monoclonal antibodies directed against a large g determinant and one directed against a determinant found on rh d+ cells but not du… More

THEIR POTENTIAL APPLICATIONS TO A SUBUNIT VACCINE

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gregory r reyes , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Human t-cell lymphotrophic virus type i (htlv-i) is the causative agent of an aggressive form of t-cell leukemia endemic to certain geographic areas but also currently increasing in frequency in the same population at risk for developing aids. sero-epidemiologic data suggest the presence of a… More

THIS PROJECT WILL PRODUCE MOUSE AND RAT MONOCLONAL ANTIBODIES TO THE LEUKEMOGENIC HUMAN RETROVIRUS, HTLV-I.

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kou hwang , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
This project will produce mouse and rat monoclonal antibodies to the leukemogenic human retrovirus, htlv-i. stable, immunoglobulin-secreting htlv-i elisa-reactive subclones will be isolated and their viral antigen specificity confirmed by immunoprecipitation, western blotting, and immunofluorescence… More

HTLV-III/LAV FOR POTENTIAL USE AS A RECOMBINANT SUBUNIT VACCINE

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gregory r reyes , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Htlv-iii/lav is a recently described human retrovirus linkedboth molecular- and seroepidemiologically to the current epidemic of aids. it should be possible not only to interfere with viral propogation in a chemotherapeutic manner but also to effect immunoprophylaxis in the at-risk population, as… More

RAPID APPROACHES FOR PRODUCTION OF GENOMIC DNA PROBES

Award Year / Program / Phase: 1987 / SBIR / Phase II
Agency: HHS
Principal Investigator: Kirk E. Fry , Senior Scientist
Award Amount: $332,000.00
Abstract:
Current methods to isolate clusters of dna fragments linked to a given marker are slow and cumbersome. methods for in situ hybridization of unique' copy gene sequences to human chromosomes are also difficult and at the limit of consistent reliability. in the present application we propose to develop… More

GENE DIVERSIFICATION BY DIRECTED RETROTRANSPOSITION

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Edward B. Cambareri
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Gene-products of recombinant origin have substantial commercial value for pharmaceutical and technical uses. Directed evolution approaches to generate new or improved products have successfully been applied in instances where… More